A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
Status:
Active, not recruiting
Trial end date:
2028-02-09
Target enrollment:
Participant gender:
Summary
This is a Phase I, multicenter, open-label, dose escalation and dose expansion study to
assess the safety and pharmacokinetic profile of PLB1004, a mono-anilino-pyrimidine compound,
given alone in NSCLC patients with EGFR exon 20 insertion mutations. Patients will be
enrolled and dosed according to the most current protocol. This study is made of two Parts.
Part 1 includes a dose escalation into 7 cohorts and patient allocation to these cohorts will
be via slot allocation. Each cohort has a minimum of 3 and a maximum of 6 patients for a
total of 21 - 42 patients. The patient population of the dose escalation phase will include
patients with advanced NSCLC harboring EGFR classical mutations or Ex20ins mutations. Part 2
includes an expansion phase and the expansion phase will explore one or more dose levels of
PLB1004 in NSCLC patients with EGFR Ex20ins mutations.